Article metrics

Extended report
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Statistics from Altmetric.com

Online download statistics by month:

Online download statistics by month: August 2015 to October 2019

AbstractFullPdf
Aug 201541361117
Sep 20151083700530
Oct 2015198131103
Nov 201511314493
Dec 2015124126120
Jan 201614111778
Feb 20161019673
Mar 2016938171
Apr 20169811694
May 2016211144120
Jun 2016236125112
Jul 2016120163101
Aug 201611519972
Sep 201610920383
Oct 201611617486
Nov 20168711986
Dec 20161656232223
Jan 2017946203176
Feb 201713212578
Mar 20171620592
Apr 20171237372
May 20171526679
Jun 20176421791
Jul 201725724974
Aug 201728525871
Sep 201728323663
Oct 201727426187
Nov 2017305274121
Dec 201719918260
Jan 201820518470
Feb 201817314973
Mar 201818614757
Apr 201834930247
May 201817815535
Jun 201818817142
Jul 201819918152
Aug 201822320758
Sep 201824219371
Oct 201824524174
Nov 201827026859
Dec 201825124559
Jan 201920620473
Feb 201920519966
Mar 201915014580
Apr 201910910775
May 201912412483
Jun 2019595849
Jul 20191118163
Aug 2019977873
Sep 2019926651
Oct 20191076858
Total1177193534594